
    
      The purpose of this trial is to assess the AVERT System device, which is designed to limit
      the volume of CM (Contrast Media) utilized, during a staged therapeutic coronary PCI
      (Percutaneous Coronary Intervention) or a coronary diagnostic procedure that is anticipated
      to become a PCI (i.e. ad hoc PCI) for the reduction of CIN (Contrast Induced Nephropathy).
    
  